Created at	Source	Raw Value	Validated value
Jan. 8, 2022, 8 a.m.	usa	Antibody levels to SARS CoV-2 Spike protein (Phase II);Fold increase of Spike IgG levels (Phase II);Incidence of adverse events (Phase I);Incidence of adverse events (Phase II)	Antibody levels to SARS CoV-2 Spike protein (Phase II);Fold increase of Spike IgG levels (Phase II);Incidence of adverse events (Phase I);Incidence of adverse events (Phase II)
Nov. 23, 2020, 12:31 a.m.	usa	Incidence of adverse events	Incidence of adverse events